A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Epistemonikos ID: bec6ee027273d6441cdc7d04116b9a05c8cff382
First added on: Aug 21, 2026